The FDA approved Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica whose symptoms are not adequately controlled by corticosteroids or who cannot tolerate tapering. In the phase III REPLENISH trial, approximately 41% of patients in both Cosentyx dose groups achieved sustained remission at week 52, compared with approximately 20% in the placebo group. Patients in the 150 mg group used an average cumulative dose of 1,683 mg of corticosteroids, compared with 2,093 mg in the placebo group.
Source:Home – GeneOnline News · Read Original
Leave a Reply